Core Viewpoint - The announcement details the completion of a legal representative change and the issuance of a new business license for Shaanxi Kanghui Pharmaceutical Co., Ltd, following the approval of several resolutions at the recent shareholder and board meetings [1][3]. Group 1: Corporate Changes - The company held its second extraordinary general meeting and the first meeting of the sixth board of directors on September 4, 2025, where resolutions regarding the cancellation of the supervisory board and amendments to the Articles of Association were approved [1]. - The legal representative of the company has been changed to Mr. Li Hongming, with all other registration details in the business license remaining unchanged [1]. Group 2: Business Information - The company is registered with a capital of 99.88 million RMB and operates as a joint-stock company [1]. - The business scope includes the production and sale of various pharmaceutical forms such as tablets, capsules, granules, oral liquids, and more, as well as services related to traditional Chinese medicine and pharmaceutical technology [1].
陕西康惠制药股份有限公司 关于完成法人变更并换领新营业执照的公告